Breast cancer screening by clinical breast examination and a new instrument named iBreastExam
Phase 4
Completed
- Registration Number
- CTRI/2020/01/022727
- Lead Sponsor
- Prayas
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10000
Inclusion Criteria
Consenting women
Exclusion Criteria
Women who have undergone breast surgery
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. The outcome will be women detected with breast cancer correctly by clinical breast examination and iBreastExam <br/ ><br> <br/ ><br>2. Test performance of clinical breast exam and iBreastExam in detecting breast cancerTimepoint: single
- Secondary Outcome Measures
Name Time Method To study the test performance of CBE and iBreastExam in detecting lumps with histopathology as the reference standard <br/ ><br>Timepoint: cross-sectional
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie iBreastExam's efficacy in detecting early-stage breast cancer compared to traditional CBE?
How does iBreastExam compare to mammography and ultrasound in terms of sensitivity and specificity for breast cancer screening in diverse populations?
Are there specific biomarkers or risk factors that correlate with improved outcomes when using iBreastExam for breast cancer detection?
What are the potential adverse events associated with iBreastExam and how do they compare to standard-of-care screening methods?
What are the implications of iBreastExam's results for the broader landscape of breast cancer screening technologies and their integration with existing diagnostic tools?